Dr. Schulze is the Chairman and Director of Institute for Psychiatric Phenomics and Genomics, LMU in Munich and a Professor of Psychiatry and Behavioral Sciences at the State University of New York.
His research has focused on genetic epidemiology and the genotype-phenotype relationship in psychiatric disorders. He coordinates a German-wide center grant on longitudinal psychosis research and spearhead an international study on the genetic basis of response to lithium treatment in bipolar disorder, comprising several research groups from Europe, the Americas, Asia, and Australia.
Furthermore, he is engaged in Germany-wide activities for sophisticated and networked biobanking for biological psychiatric research. To study the ethical and societal implications of contemporary large-scale “omics” projects, he is involved in consortia addressing these issues from various angles, bridging existing gaps between biomedical sciences, research on ethics and law.
At WBMA, Dr. Schulze, coordinates our research efforts to create the next generation of individualized medicine algorithms for diagnosis and treatment through exome and whole genome sequencing.
